The synthetic lethal interaction between CREBBP and EP300 genes, two frequently mutated epigenetic modulators in B-cell lymphoma, was further validated in the previously published CRISPR-Cas9 screens and inhibitor assays. The gene discussed is CREBBP; the disease is B-cell non-Hodgkin lymphoma.